A method for efficiently producing esomeprazole sodium based on mobile phase

By using chitosan-supported chiral ionic liquid titanium catalyst in a microchannel reactor for oxidation reaction, the problems of low yield and unstable purity in the preparation of esomeprazole sodium were solved, achieving efficient and stable production of esomeprazole sodium, reducing costs and improving catalyst lifespan and production efficiency.

CN114524801BActive Publication Date: 2024-11-29HUBEI ENG UNIV +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202210072823.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-01-21
Publication Date
2024-11-29
Estimated Expiration
2042-01-21

AI Technical Summary

Technical Problem

Existing methods for preparing esomeprazole sodium suffer from low yield, high cost, high operational complexity, and difficulty in ensuring product purity and stability, especially in achieving efficient and continuous production in industrial settings.

Method used

An oxidation reaction was carried out in a microchannel reactor using a chiral ionic liquid titanium catalyst supported on chitosan. By continuously injecting omeprazole sulfide and hydrogen peroxide solution, combined with sodium hydroxide alkalization and activated carbon impurity removal, the efficient production of esomeprazole sodium was achieved.

Benefits of technology

High yield (over 98.5%) and high enantioselectivity (over 99%) of esomeprazole sodium were achieved at room temperature. The catalyst is recyclable, reducing production costs and improving production efficiency and product quality stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114524801B_ABST
    Figure CN114524801B_ABST
Patent Text Reader

Abstract

The invention discloses a method for efficiently producing esomeprazole sodium based on mobile phase, the method mainly comprising the following steps: S1, prepare chitosan-loaded chiral ionic liquid titanium catalyst, and fill the catalyst into a microchannel reactor; S2, two raw materials omeprazole sulfide and a hydrogen peroxide solution with a mass fraction of 30wt.% are continuously injected into a microchannel reactor in proportion to continuously carry out oxidation reaction; S3, after the product passes through a microchannel, a chiral (S)-omeprazole drug with high yield and high enantioselectivity is obtained; S4, the product is collected, dissolved in an organic solvent, alkalized with sodium hydroxide, and a crude esomeprazole sodium product is obtained; S5, activated carbon impurity removal, purification, and fine esomeprazole sodium are obtained. The method realizes the preparation of fine esomeprazole sodium under room temperature and greening environmental protection conditions, and the esomeprazole sodium yield can be as high as 98.5%, the enantioselectivity is as high as 99%, and the catalyst can be recycled for many times.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of pharmaceutical chemistry, and in particular to a method for efficiently producing esomeprazole sodium based on a mobile phase. Background Art

[0002] Gastric ulcer is a chronic digestive system disease with a high incidence and recurrence rate in clinical practice, which can cause complications such as gastric perforation, gastric bleeding, and cancer. Proton pump inhibitors are currently the most advanced class of drugs for the treatment of peptic gastric ulcers. Among the proton pump inhibitors currently available in the domestic market, esomeprazole sodium is the most widely used, with the advantages of rapid onset, strong effect, and longer lasting effect. Omeprazole is a 1:1 mixture of two optical isomers, R and S, and its S optical isomer is esomeprazole.

[0003] The method for preparing esomeprazole sodium at present is mainly divided into inclusion complex splitting method (CN-01087739) and asymmetric oxidation method. The inclusion complex splitting method mainly splits through inclusion complexing from the prepared omeprazole, or splits through simulated moving bed chromatography to obtain esomeprazole, and the method does not undergo chemical reaction, is only formed by intermolecular forces, and is easy to pass through a column, and the modes such as solvent exchange reach the purpose of separation. However, the column method limits the output of preparing esomeprazole sodium, and limits its industrial production benefit. Another method is an asymmetric catalytic oxidation method (such as WO9602535, WO03 / 089408), which is then prepared by sodium hydroxide solution salt formation, and the key is to prepare a catalyst with low cost and excellent performance, obtain chiral single S-omeprazole through asymmetric catalysis, and adopt various characterization means to determine product configuration and purity. Currently, this method also has obvious defects: 1) the amount of chiral ligand used is too large, even reaching the chemical dosage; 2) it uses relatively expensive cumene peroxide (CHP); 3) it requires a large amount of special organic base: diisopropylethylamine, which increases the cost and operational complexity.

[0004] When the selective oxidant cumene peroxide (CHP) is replaced with hydrogen peroxide, m-chloroperoxybenzoic acid (m-CPBA), sodium peroxide, etc., the Ee value of the reaction solution is significantly reduced (Ee is enantiomeric selectivity), and the purpose of selective oxidation to (S)-type isomers cannot be achieved. Currently, more conventional synthetic methods have been reported, and the specific routes are as follows:

[0005]

[0006] If the crude product of esomeprazole free base prepared by selective oxidation is directly used to prepare esomeprazole sodium, according to this process, the isomer is about 2%, and the purity is only 93%. If a mixed solvent of methanol and isopropyl ether is selected for further refining, it is found that the yield is not high, and the process is unstable, and the isomer can be removed sometimes and cannot be removed sometimes. Although the conventional method for preparing esomeprazole sodium salt has a short route, the actual amplification operation yield is low, and it is difficult to ensure the quality stability of the finished product. Patent CN103044402B selects cumene hydroperoxide for chiral oxidation reaction. The yield of chiral oxidation reaction does not exceed 85%, and a strong oxidant diisopropylamine is also used, which has certain toxicity.

[0007] Patent CN1810803B reported the use of chiral bidentate ligands, tetraisopropoxytitanium (Ti(O i Pr)4), omeramidazole thioether, oxidant (TBHP: tert-butyl hydroperoxide, CHP) reaction, can obtain omeramidazole. Although this reaction pathway does not need to add organic base, it needs to use expensive organic oxidant and special ligand.

[0008] The preparation method of esomeprazole sodium reported in the existing patent is to complete one-time production by feeding the materials once, which has problems such as discontinuous production and low efficiency, thus restricting the production efficiency of the company. Summary of the invention

[0009] The purpose of the present invention is to overcome the above technical deficiencies, provide a method for efficiently producing esomeprazole sodium based on a mobile phase, and solve the technical problem of the yield of esomeprazole sodium in the prior art.

[0010] In order to achieve the above technical purpose, the technical solution of the present invention provides a method for efficiently producing esomeprazole sodium based on a mobile phase, comprising the following steps:

[0011] A method for efficiently producing esomeprazole sodium based on a mobile phase comprises the following steps:

[0012] S1, filling chitosan-supported chiral ionic liquid titanium catalyst into a microchannel reactor;

[0013] S2, simultaneously and continuously injecting the raw material omeprazole sulfide and a 25-35wt% hydrogen peroxide solution into the microchannel reactor for oxidation reaction;

[0014] S3, the reaction is completed in the microchannel reactor to obtain the chiral (S)-omeprazole drug;

[0015] S4, collecting the product, dissolving it in an organic solvent, and alkalizing it with sodium hydroxide to obtain a crude product of esomeprazole sodium;

[0016] S5, removing impurities with activated carbon and purifying to obtain the refined esomeprazole sodium;

[0017] The general formula of the chitosan-supported chiral ionic liquid titanium catalyst is:

[0018]

[0019] In formula (1), each * independently represents R configuration or S configuration, and two * are the same;

[0020] CS is chitosan;

[0021] R1 is selected from hydrogen, alkyl, aryl, aryl-substituted alkyl;

[0022] R2 is selected from a hydrogen atom or an alkyl group;

[0023] R3 is selected from C1~C 16 An alkyl or substituted aryl group;

[0024] The structural formula of the raw material omeprazole sulfide is:

[0025]

[0026] Compared with traditional homogeneous catalysts, in general, for the same reaction, the catalytic activity of heterogeneous catalysts is not as good as that of homogeneous catalysts. The chitosan-loaded chiral ionic liquid titanium catalyst used in the above technical scheme contains an ionic liquid, and the ionic liquid has good compatibility with both the oil phase and the aqueous phase, which enables the catalyst to be in good contact with both the organic reaction substrate and the aqueous oxidant. The catalyst thereby reduces the mass transfer resistance during the reaction and accelerates the reaction; and because the catalyst is a heterogeneous catalyst, the concentration of the local reaction can be increased, thereby achieving a higher catalytic activity than a homogeneous catalyst, and can be separated and recovered from the liquid phase for recycling. Specifically, in step S1, the steps for making the chitosan-loaded chiral ionic liquid titanium catalyst include:

[0027] a) reacting 1-vinylimidazole with bromopropionic acid to generate a double-bonded ionic liquid compound containing a carboxylic acid group: 1-vinyl-3-propionic acid imidazole bromide;

[0028] b) The double-bonded ionic liquid compound containing a carboxylic acid group reacts with chitosan dissolved in a dilute acid solution to obtain a chitosan-functionalized vinyl ionic liquid II, the general formula of which is:

[0029]

[0030] c) reacting the obtained chitosan functionalized vinyl ionic liquid II with a chiral amino acid to obtain a chitosan functionalized chiral amino acid vinyl ionic liquid, the reaction formula being:

[0031]

[0032] d) Based on the controlled fragmentation-chain transfer free radical polymerization method (RAFT), azobisisobutyronitrile is used as a chain initiator and carbon thioester is used as a molecular weight regulator to controllably polymerize the chiral amino acid vinyl ionic liquid functionalized with chitosan obtained in step c) to generate a polymer, wherein the carbon thioester has the following general formula: The reaction formula of the polymer by controlled fracture-chain transfer free radical polymerization is:

[0033]

[0034] e) finally complexing the polymer obtained in step d) with a metal titanium salt to obtain the chitosan-supported chiral ionic liquid titanium catalyst.

[0035] The above technical solution uses chitosan, which is widely available, as a carrier, and utilizes the superior properties of ionic liquids and the cheap and readily available characteristics of natural chiral amino acids to prepare a high-performance, sustainable catalyst.

[0036] Specifically, in step c), the chiral amino acid used is a natural chiral L-amino acid.

[0037] Specifically: the chiral amino acid is selected from L-proline, L-phenylalanine, L-leucine, L-histidine, and L-isoleucine.

[0038] Specifically, in step (e), the metal titanium salt used is tetraisopropoxytitanium.

[0039] Specifically, in step S2, the raw material omeprazole sulfide and a 25-35 wt% hydrogen peroxide solution are continuously injected into the microchannel reactor at a ratio of 1:1.2 for oxidation reaction. Preferably, a 25-35 wt% hydrogen peroxide solution is used.

[0040] Specifically, in step S2, the solvent used in the reaction is water, and the flow rate of the solution is 1-3 mL / min.

[0041] Specifically, in step S2, the temperature in the reactor is maintained at room temperature.

[0042] Specifically, in step S4, the organic solvent is selected from dichloromethane, anhydrous ethanol, tetrahydrofuran or toluene.

[0043] Specifically, in step S5, R3 is selected from isopropyl, isobutyl, tert-butyl or benzyl.

[0044] Compared with the prior art, the advantages of the present invention are:

[0045] The present invention adopts the chitosan-loaded chiral ionic liquid titanium catalyst to efficiently produce esomeprazole sodium in a continuous mobile phase. Under room temperature conditions, the yield can be as high as 98.5%, the enantioselectivity can be as high as 99%, and the catalyst can be recycled for multiple times. The yield of (S)-omeprazole drug prepared by using the chiral L-proline titanium catalyst of polyionic liquid without chitosan loading is 46.7%, and the enantioselectivity is 84.2%. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1 It is the nuclear magnetic resonance of esomeprazole sodium in the present invention 1 H NMR spectrum;

[0047] Figure 2 It is the nuclear magnetic resonance of esomeprazole sodium in the present invention 13 C NMR spectrum. DETAILED DESCRIPTION

[0048] This specific embodiment provides a method for efficiently producing esomeprazole sodium based on a mobile phase, comprising the following steps:

[0049] S1. Prepare an efficient chitosan-loaded chiral ionic liquid titanium catalyst and fill the catalyst into a microchannel reactor; the catalyst preparation path is: react vinyl imidazole with bromopropionic acid to generate a double-bonded ionic liquid containing a carboxylic acid group, then react with chitosan to obtain a chitosan-functionalized vinyl ionic liquid, react the obtained chitosan-functionalized vinyl ionic liquid with a chiral amino acid to obtain a chitosan-functionalized chiral amino acid vinyl ionic liquid, then perform a polymerization reaction to generate a polymer, and finally complex with a metal titanium salt to obtain a chitosan-functionalized polyionic liquid chiral amino acid titanium catalyst.

[0050] S2, continuously introducing two raw materials, omeprazole sulfide and a 30wt.% hydrogen peroxide solution at a ratio of 1:1.2 into the microchannel reactor at a pressure of 100KPa-120KPa through a mechanical pump, and continuously injecting them into the microchannel reactor for oxidation reaction;

[0051] S3, after the product passes through the microchannel, the product is collected at the sample outlet to obtain a chiral (S)-omeprazole drug with high yield and high enantioselectivity;

[0052] S4, dissolving the collected product in an organic solvent, and alkalizing with sodium hydroxide to obtain a crude product of esomeprazole sodium;

[0053] S5. Remove impurities with activated carbon and purify to obtain the fine product esomeprazole sodium.

[0054] For safety reasons, if the pressure inside the microchannel reactor is set to be greater than 120KPa, or the temperature is greater than 110°C, an alarm will be sounded, the input of gas and liquid will be stopped, and heating will be stopped at the same time.

[0055] The structural formula of the raw material omeprazole sulfide is as follows:

[0056]

[0057] The structural formula of the product (S)-omeprazole is as follows:

[0058]

[0059] The product yield obtained by the microchannel reactor is above 98.5%, and the enantioselectivity is above 99%, and the next step of production can be directly carried out. If the amount of the raw material compound omeprazole sulfide and the oxidant hydrogen peroxide is properly controlled, the reaction will not overoxidize to generate the byproduct omeprazole sulfone.

[0060] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0061] Example 1

[0062] This specific embodiment provides a method for efficiently producing esomeprazole sodium based on a mobile phase, comprising the following synthetic pathways and steps:

[0063] The chiral amino acid titanium catalyst of chitosan ionic liquid type has a structure of general formula (1):

[0064]

[0065] In the formula (1) of this embodiment:

[0066] CS is chitosan;

[0067] R1 corresponds to L-proline, specifically tetrahydropyrrolyl; correspondingly, both * are in S configuration;

[0068] R2 and R3 correspond to benzylidene thiopropionate, and the specific structure of benzylidene thiopropionate is:

[0069]

[0070] S1. Prepare an efficient chiral ionic liquid titanium catalyst supported by chitosan: add 10 mmol of redistilled 3-bromopropionic acid and 10 ml of acetonitrile as solvent to a 250 ml three-necked flask, slowly add 1.1 mmol of 1-vinyl imidazole with a constant pressure dropping funnel under heating and reflux at 80°C, and reflux with magnetic stirring at 60°C for 5 h. After the reaction, extract twice with anhydrous ether (2×10 ml), take the yellow oily substance, and vacuum dry at 70°C for 24 h to obtain a yellow viscous liquid, i.e., a double-bond ionic liquid compound containing a carboxylic acid group: 1-vinyl-3-propionic acid imidazole bromide, the structure of which is shown below: The newly prepared 1-vinyl-3-propionic acid imidazolium bromide was dissolved in a dilute acid solution with 1 g of chitosan and reacted for 24 hours to obtain an ionic liquid containing chitosan. The chitosan modified with 1-vinyl-3-propionic acid imidazolium bromide retained the hydroxyl group and some unsubstituted amino groups of chitosan as well as the newly added imidazole groups with pH responsiveness, and the chitosan functionalized vinyl ionic liquid II was obtained:

[0071]

[0072] The obtained chitosan functionalized vinyl ionic liquid II 10mmol and 10mmol L-proline aqueous solution were slowly added dropwise to the flask, and the reaction formula 1 was obtained by TLC tracking:

[0073]

[0074] The chiral L-proline vinyl ionic liquid functionalized with chitosan was obtained. The reaction was continued under stirring at room temperature for 15 hours, and the solvent was dried by rotary evaporator. The liquid was dried under vacuum, and then a mixed solvent of methanol:acetonitrile = 9:1 was added to the system. The mixture was vigorously stirred at room temperature for 2 hours to precipitate the unreacted amino acid. The mixture was filtered, the solvent was dried by rotary evaporation, and the pure product was obtained by vacuum drying at 80°C for 24 hours.

[0075] The chiral L-proline vinyl ionic liquid functionalized with chitosan prepared above (5 mmol) was dissolved in anhydrous methanol, and benzyl thiopropionate (chain transfer agent, 1 / 6 mmol, 0.0330 g) and AIBN (chain initiator, 1 / 30 mmol, 0.0052 g) were added to the reaction solution. Under N2 protection, the reaction solution was placed in a Schlenk tube and reacted at 60°C for 24 h. After the reaction was completed, the reaction solution was concentrated in vacuum to obtain a light yellow solid product, which was then dried in vacuum at 30°C to obtain a polymer.

[0076] 4 mmol of the polymer prepared above was dissolved in 30 ml of anhydrous dichloromethane, and 2 mmol of metal titanium salt (tetraisopropyl titanate) was added thereto, and the reaction was refluxed for 3 hours. After the reaction was completed, the solvent was dried by spin drying and vacuum dried at 30°C to obtain chitosan functionalized polyionic liquid chiral L-proline titanium catalyst: The product was characterized by infrared: FT-IR (KBr): γ max / cm -1 3406 (characteristic peak of -OH in L-proline), 3365 (characteristic peak of -NH- stretching vibration in chitosan), 3152, 2961, 1645 (characteristic peak of -C=O in L-proline), 1623 (characteristic peak of -NH- stretching vibration in L-proline), 1565 (skeleton vibration of imidazole ring in ionic liquid), 1463 (characteristic peak of methylene vibration in imidazole ionic liquid), 1377, 1335, 1163 (skeleton stretching vibration of imidazole ring), 1106, 1023, 904 (characteristic peak of Ti-O in complex), 893 (stretching vibration peak of chitosan ring), 708 (characteristic peak of Ti-O in complex), 646 (characteristic peak of imidazole ring) cm -1 .

[0077] The above-mentioned heterogeneous catalyst structure contains an ionic liquid, which has good compatibility with both the oil phase and the water phase, which promotes good contact between the organic reaction substrate and the aqueous oxidant. Therefore, the catalyst reduces the mass transfer resistance during the reaction and accelerates the reaction, so that cheaper and more readily available aqueous oxidants can be used. The heterogeneous catalyst in this application can increase the concentration of tetraisopropoxytitanium that is locally complexed with the chiral ligand, thereby reflecting a higher catalytic activity than the homogeneous catalyst. In addition, the heterogeneous catalyst is easy to recycle and can be reused.

[0078] S2, chitosan-supported chiral ionic liquid titanium catalyst is filled into a microchannel reactor, and two raw materials, omeprazole sulfide and a 30wt.% hydrogen peroxide solution are continuously introduced into the microchannel reactor at a pressure of 100KPa-120KPa through a mechanical pump, and the ratio is 1:1.2, and the oxidation reaction is continuously carried out in the microchannel reactor;

[0079] S3, after the product passes through the microchannel, the product is collected at the sample outlet to obtain a chiral (S)-omeprazole drug with high yield and high enantioselectivity;

[0080] S4, dissolving the collected product in an organic solvent, and alkalizing with sodium hydroxide to obtain a crude product of esomeprazole sodium;

[0081] S5. Remove impurities with activated carbon and purify to obtain the fine product esomeprazole sodium.

[0082] The yield of the prepared chiral (S)-omeprazole drug is 98.5%, and the enantioselectivity is 99%.

[0083] The hydrogen spectrum of (S)-omeprazole is as follows Figure 1 As shown, the carbon spectrum is Figure 2 , the solvent used was deuterated chloroform, and the spectrum showed that (S)-omeprazole drug was successfully prepared.

[0084] Without replacing the heterogeneous catalyst in the same microchannel reactor, the preparation method of Example 1 was repeated 20 times, and the yield of the prepared (S)-omeprazole drug was above 96%.

[0085] Example 2

[0086] This embodiment proposes a second method for efficiently producing esomeprazole sodium, comprising the following steps:

[0087] Preparation of efficient chiral ionic liquid titanium catalyst supported on chitosan: According to step S1 of Example 1, 5 mol of vinyl imidazole was reacted with 5 mol of bromopropionic acid to generate a double-bonded ionic liquid containing a carboxylic acid group, which was then reacted with 5 mol of chitosan to obtain a chitosan-functionalized vinyl ionic liquid. The obtained chitosan-functionalized vinyl ionic liquid was reacted with L-phenylalanine to obtain a chitosan-functionalized chiral L-phenylalanine vinyl ionic liquid, followed by a reversible addition polymerization reaction, a chain transfer agent (thiopropionic acid benzyl ester, 1 / 6 mmol, 0.0330 g), a chain initiator (AIBN, 1 / 30 mmol, 0.0052 g), to generate a polymer, and finally complexed with a metal titanium salt to obtain a chitosan-functionalized polyionic liquid chiral L-phenylalanine titanium catalyst. The product was characterized by infrared FT-IR (KBr): γ max / cm -1 3407 (characteristic peak of -OH in L-phenylalanine), 3362 (characteristic peak of -NH- stretching vibration in chitosan), 3150, 2926 (characteristic peak of -CH2- in L-phenylalanine), 1647 (characteristic peak of -C=O in L-phenylalanine), 1625 (characteristic peak of -NH- stretching vibration in L-phenylalanine), 1563 (skeleton vibration of imidazole ring in ionic liquid), 1460 (characteristic peak of methylene vibration in imidazole ionic liquid), 1375, 1334, 1165 (skeleton stretching vibration of imidazole ring), 1106, 1024, 902 (characteristic peak of Ti-O in the complex), 895 (stretching vibration peak of chitosan ring), 710 (characteristic peak of Ti-O in the complex), 645 (characteristic peak of imidazole ring) cm -1 The product is shown in Formula 1, and R1 is a benzyl group.

[0088] S2, chitosan-supported chiral ionic liquid titanium catalyst is filled into a microchannel reactor, and two raw materials, omeprazole sulfide and a 30wt.% hydrogen peroxide solution are continuously introduced into the microchannel reactor at a pressure of 100KPa-120KPa through a mechanical pump, and the ratio is 1:1.2, and the oxidation reaction is continuously carried out in the microchannel reactor;

[0089] S3, after the product passes through the microchannel, the product is collected at the sample outlet to obtain a chiral (S)-omeprazole drug with high yield and high enantioselectivity;

[0090] S4, dissolving the collected product in an organic solvent, and alkalizing with sodium hydroxide to obtain a crude product of esomeprazole sodium;

[0091] S5. Remove impurities with activated carbon and purify to obtain the fine product esomeprazole sodium.

[0092] The yield of the prepared chiral (S)-omeprazole drug is 98%, and the enantioselectivity is 99%.

[0093] The hydrogen spectrum of (S)-omeprazole is as follows Figure 1 , carbon spectrum Figure 2 As shown, the solvent used is deuterated chloroform, and the spectrum shows that the (S)-omeprazole drug is successfully prepared.

[0094] Without replacing the heterogeneous catalyst in the same microchannel reactor, the preparation method of Example 1 was repeated 20 times, and the yield of the prepared (S)-omeprazole drug was above 95%.

[0095] Example 3

[0096] This embodiment proposes a third method for efficiently producing esomeprazole sodium, comprising the following steps:

[0097] Preparation of efficient chiral ionic liquid titanium catalyst supported by chitosan: According to step S1 of Example 1, 5 mol of vinyl imidazole is reacted with 5 mol of bromopropionic acid to generate a double-bonded ionic liquid containing a carboxylic acid group, which is then reacted with 5 mol of chitosan to obtain a chitosan-functionalized vinyl ionic liquid, and the obtained chitosan-functionalized vinyl ionic liquid is reacted with L-leucine to obtain a chitosan-functionalized chiral L-leucine vinyl ionic liquid, followed by a reversible addition polymerization reaction, a chain transfer agent (thiopropionic acid benzyl ester, 1 / 6 mmol, 0.0330 g), a chain initiator (AIBN, 1 / 30 mmol, 0.0052 g), to generate a polymer, and finally complexed with a metal titanium salt to obtain a chitosan-functionalized polyionic liquid chiral L-leucine titanium catalyst, as shown in Formula 1. The product is characterized by infrared: FT-IR (KBr): γ max / cm -13395 (characteristic peak of -OH in L-leucine), 3368 (characteristic peak of -NH- stretching vibration in chitosan), 3156, 2923 (characteristic peak of -CH2- in L-phenylalanine), 1694 (characteristic peak of -C=O in L-leucine), 1620 (characteristic peak of -NH- stretching vibration in L-leucine), 1566 (skeleton vibration of imidazole ring in ionic liquid), 1463 (characteristic peak of methylene vibration in imidazole ionic liquid), 1374, 1337, 1163 (skeleton stretching vibration of imidazole ring), 1104, 1022, 904 (characteristic peak of Ti-O in complex), 890 (stretching vibration peak of chitosan ring), 709 (characteristic peak of Ti-O in complex), 643 (characteristic peak of imidazole ring) cm -1 The product is shown in Formula 1, and R1 is tert-butyl.

[0098] S2, chitosan-supported chiral ionic liquid titanium catalyst is filled into a microchannel reactor, and two raw materials, omeprazole sulfide and a 30wt.% hydrogen peroxide solution are continuously introduced into the microchannel reactor at a pressure of 100KPa-120KPa through a mechanical pump, and the ratio is 1:1.2, and the oxidation reaction is continuously carried out in the microchannel reactor;

[0099] S3, after the product passes through the microchannel, the product is collected at the sample outlet to obtain a chiral (S)-omeprazole drug with high yield and high enantioselectivity;

[0100] S4, dissolving the collected product in an organic solvent, and alkalizing with sodium hydroxide to obtain a crude product of esomeprazole sodium;

[0101] S5. Remove impurities with activated carbon and purify to obtain the fine product esomeprazole sodium.

[0102] The yield of the prepared chiral (S)-omeprazole drug is 97%, and the enantioselectivity is 99%.

[0103] The hydrogen spectrum of (S)-omeprazole is as follows Figure 1 , carbon spectrum Figure 2 As shown, the solvent used is deuterated chloroform, and the spectrum shows that the (S)-omeprazole drug is successfully prepared.

[0104] Without replacing the heterogeneous catalyst in the same microchannel reactor, the preparation method of Example 1 was repeated 20 times, and the yield of the prepared (S)-omeprazole drug was above 96%.

[0105] Example 4

[0106] This embodiment proposes a fourth method for efficiently producing esomeprazole sodium, comprising the following steps:

[0107] Preparation of efficient chiral ionic liquid titanium catalyst supported by chitosan: According to step S1 of Example 1, 5 mol of vinyl imidazole is reacted with 5 mol of bromopropionic acid to generate a double-bonded ionic liquid containing a carboxylic acid group, which is then reacted with 5 mol of chitosan to obtain a chitosan-functionalized vinyl ionic liquid, and the obtained chitosan-functionalized vinyl ionic liquid is reacted with L-histidine to obtain a chitosan-functionalized chiral L-histidine vinyl ionic liquid, followed by a reversible addition polymerization reaction, a chain transfer agent (thiopropionic acid benzyl ester, 1 / 6 mmol, 0.0330 g), a chain initiator (AIBN, 1 / 30 mmol, 0.0052 g), to generate a polymer, and finally complexed with a metal titanium salt to obtain a chitosan-functionalized polyionic liquid chiral L-histidine titanium catalyst, as shown in Formula 1. The product is characterized by infrared: FT-IR (KBr): γ max / cm -1 3392 (characteristic peak of -OH in L-histidine), 3365 (characteristic peak of -NH- stretching vibration in chitosan), 3153, 3054 (characteristic peak of -CH2- in L-histidine), 1696 (characteristic peak of -C=O in L-histidine), 1624 (characteristic peak of -NH- stretching vibration in L-histidine), 1560 (skeleton vibration of imidazole ring in ionic liquid), 1461 (characteristic peak of methylene vibration in imidazole ionic liquid), 1372, 1335, 1161 (stretching vibration of imidazole ring), 1102, 1021, 905 (characteristic peak of Ti-O in the complex), 892 (stretching vibration peak of chitosan ring), 705 (characteristic peak of Ti-O in the complex), 645 (characteristic peak of imidazole ring) cm -1 The product is shown in Formula 1, and R1 is methylimidazole.

[0108] S2, chitosan-supported chiral ionic liquid titanium catalyst is filled into a microchannel reactor, and two raw materials, omeprazole sulfide and a 30wt.% hydrogen peroxide solution are continuously introduced into the microchannel reactor at a pressure of 100KPa-120KPa through a mechanical pump, and the ratio is 1:1.2, and the oxidation reaction is continuously carried out in the microchannel reactor;

[0109] S3, after the product passes through the microchannel, the product is collected at the sample outlet to obtain a chiral (S)-omeprazole drug with high yield and high enantioselectivity;

[0110] S4, dissolving the collected product in an organic solvent, and alkalizing with sodium hydroxide to obtain a crude product of esomeprazole sodium;

[0111] S5. Remove impurities with activated carbon and purify to obtain the fine product esomeprazole sodium.

[0112] The yield of the prepared chiral (S)-omeprazole drug is 96%, and the enantioselectivity is 98%.

[0113] The hydrogen spectrum of (S)-omeprazole is as follows Figure 1 , carbon spectrum Figure 2 As shown, the solvent used is deuterated chloroform, and the spectrum shows that the (S)-omeprazole drug is successfully prepared.

[0114] Without replacing the heterogeneous catalyst in the same microchannel reactor, the preparation method of Example 1 was repeated 20 times, and the yield of the prepared (S)-omeprazole drug was above 95%.

[0115] Example 5

[0116] This embodiment proposes a fifth method for efficiently producing esomeprazole sodium, comprising the following steps:

[0117] Preparation of efficient chiral ionic liquid titanium catalyst supported by chitosan: According to step S1 of Example 1, 5 mol of vinyl imidazole is reacted with 5 mol of bromopropionic acid to generate a double-bonded ionic liquid containing a carboxylic acid group, which is then reacted with 5 mol of chitosan to obtain a chitosan-functionalized vinyl ionic liquid, and the obtained chitosan-functionalized vinyl ionic liquid is reacted with L-isoleucine to obtain a chitosan-functionalized chiral L-isoleucine vinyl ionic liquid, followed by a reversible addition polymerization reaction, a chain transfer agent (thiopropionic acid benzyl ester, 1 / 6 mmol, 0.0330 g), a chain initiator (AIBN, 1 / 30 mmol, 0.0052 g), to generate a polymer, and finally complexed with a metal titanium salt to obtain a chitosan-functionalized polyionic liquid chiral L-isoleucine titanium catalyst, as shown in Formula 1. The product is characterized by infrared: FT-IR (KBr): γ max / cm -1 3397 (characteristic peak of -OH in L-isoleucine), 3365 (characteristic peak of -NH- stretching vibration in chitosan), 3154, 2922 (characteristic peak of -CH2- in L-phenylalanine), 1695 (characteristic peak of -C=O in L-leucine), 1626 (characteristic peak of -NH- stretching vibration in L-leucine), 1562 (skeleton vibration of imidazole ring in ionic liquid), 1463 (characteristic peak of methylene vibration in imidazole ionic liquid), 1372, 1335, 1163 (stretching vibration of imidazole ring), 1104, 1022, 904 (characteristic peak of Ti-O in complex), 890 (stretching vibration peak of chitosan ring), 709 (characteristic peak of Ti-O in complex), 643 (characteristic peak of imidazole ring) cm -1 The product is shown in Formula 1, and R1 is sec-butyl.

[0118] S2, chitosan-supported chiral ionic liquid titanium catalyst is filled into a microchannel reactor, and two raw materials, omeprazole sulfide and a 30wt.% hydrogen peroxide solution are continuously introduced into the microchannel reactor at a pressure of 100KPa-120KPa through a mechanical pump, and the ratio is 1:1.2, and the oxidation reaction is continuously carried out in the microchannel reactor;

[0119] S3, after the product passes through the microchannel, the product is collected at the sample outlet to obtain a chiral (S)-omeprazole drug with high yield and high enantioselectivity;

[0120] S4, dissolving the collected product in an organic solvent, and alkalizing with sodium hydroxide to obtain a crude product of esomeprazole sodium;

[0121] S5. Remove impurities with activated carbon and purify to obtain the fine product esomeprazole sodium.

[0122] The yield of the chiral (S)-omeprazole drug prepared is 96.5%, and the enantioselectivity is 98.2%.

[0123] The hydrogen spectrum of (S)-omeprazole is as follows Figure 1 , carbon spectrum Figure 2 As shown, the solvent used is deuterated chloroform, and the spectrum shows that the (S)-omeprazole drug is successfully prepared.

[0124] Without replacing the heterogeneous catalyst in the same microchannel reactor, the preparation method of Example 1 was repeated 20 times, and the yield of the prepared (S)-omeprazole drug was above 94%.

[0125] Comparative Example 1

[0126] The difference between this comparative example and Example 1 is that the heterogeneous catalyst does not contain chitosan, and other conditions and processes are the same.

[0127] The preparation process of the chiral ionic liquid titanium catalyst of the comparative example is as follows:

[0128] Add 5 mol of redistilled bromoethane (0.77 kg) and 20 ml of ethyl acetate as solvent to a 250 ml three-necked flask, and slowly add 5 mol of vinyl imidazole (0.47 kg) of ethyl acetate solution under heating and reflux at 80 ° C with a constant pressure dropping funnel. After white milky turbidity appears, continue heating and reflux stirring for 8 hours. After the reaction is completed, stop stirring and the solution will separate into two phases. The lower colorless viscous liquid is the crude product. Transfer it to a vacuum drying oven at 50 ° C and dry it in vacuum for 24 hours to obtain a white solid. Filter the product, rinse with a small amount of petroleum ether, and finally recrystallize with 20 ml of acetonitrile and 20 mL of ethyl acetate to obtain a white crystalline product. Exchange with 201×7 type anion exchange resin to obtain a double bond ionic liquid compound: 1-vinyl-3-ethyl imidazole bromide, the structure of which is shown below: R1 is ethyl;

[0129] Slowly drop a solution of 10 mmol of the obtained double-bond ionic liquid compound and 10 mmol of L-proline into a flask and track with TLC to obtain a chiral L-proline vinyl ionic liquid. Continue to react at room temperature with stirring for 15 hours, then use a rotary evaporator to dry the water, vacuum dry the above liquid, and then add a mixed solvent of methanol: acetonitrile = 9:1 to the system, vigorously stir at room temperature for 2 hours to precipitate the unreacted amino acid, filter, dry the solvent, and vacuum dry at 80°C for 24 hours to obtain a pure product.

[0130] The prepared chiral L-proline vinyl ionic liquid (5 mmol) was dissolved in anhydrous methanol, and benzyl thiopropionate (chain transfer agent, 1 / 6 mmol, 0.0330 g) and AIBN (chain initiator, 1 / 30 mmol, 0.0052 g) were added to the reaction solution. Under N2 protection, the reaction solution was placed in a Schlenk tube and reacted at 60°C for 24 h. After the reaction, the reaction solution was concentrated in vacuo to obtain a light yellow solid product, which was then dried in vacuo at 30°C to obtain a polymer.

[0131] 4 mmol of the polymer prepared above was dissolved in 30 ml of anhydrous ethanol / ethyl acetate, and 2 mmol of metal titanium salt (tetraisopropoxytitanium) was added thereto, and the reaction was refluxed for 2 h. After the reaction was completed, the solvent was dried by spin drying and vacuum dried at 30 ° C to obtain a polyionic liquid chiral L-proline titanium catalyst: The product was characterized by infrared: FT-IR (KBr): γ max / cm -1 3405 (characteristic peak of -OH in L-proline), 3150, 1647 (characteristic peak of -C=O in L-proline), 1621 (characteristic peak of -NH- stretching vibration in L-proline), 1563 (skeleton vibration of imidazole ring in ionic liquid), 1461 (characteristic peak of methylene vibration in imidazole ionic liquid), 1375, 1334, 1162 (skeleton stretching vibration of imidazole ring), 1104, 1022, 905 (characteristic peak of Ti-O in complex), 706 (characteristic peak of Ti-O in complex), 644 (characteristic peak of imidazole ring) cm -1 .

[0132] The prepared polyionic liquid chiral L-proline titanium catalyst was filled into a microchannel reactor, and the fine product esomeprazole sodium was prepared according to steps S2 to S5 of Example 1.

[0133] The yield of the prepared (S)-omeprazole drug is 46.7%, and the enantioselectivity is 84.2%.

[0134] Other beneficial effects:

[0135] 1. The production pressure is greatly reduced from the reaction conditions of 5 atmospheres to about 1 atmosphere, which can reduce production risks and extend the service life of the instrument.

[0136] 2. Use heterogeneous catalysts instead of homogeneous catalysts to facilitate the separation of catalysts and products.

[0137] 3. The use of microchannel reaction devices can reduce labor and make all production processes automated and intelligent, which reduces labor costs, reduces production risks, and increases output.

[0138] 4. Biomass-based catalysts are widely available, low cost, and can be reused more than 20 times, effectively increasing product revenue.

[0139] The specific implementation of the present invention described above does not constitute a limitation on the protection scope of the present invention. Any other corresponding changes and modifications made based on the technical concept of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. A method for efficiently producing esomeprazole sodium based on a mobile phase, characterized in that: The following steps are involved: S1, filling chitosan-supported chiral ionic liquid titanium catalyst into a microchannel reactor; S2, simultaneously and continuously injecting the raw material omeprazole sulfide and a 25-35wt% hydrogen peroxide solution into the microchannel reactor for oxidation reaction; S3, the reaction is completed in the microchannel reactor to obtain the chiral (S)-omeprazole drug; S4, collecting the product, dissolving it in an organic solvent, and alkalizing it with sodium hydroxide to obtain a crude product of esomeprazole sodium; S5, removing impurities with activated carbon and purifying to obtain the refined esomeprazole sodium; The structural formula of the raw material omeprazole sulfide is: In step S1, the preparation steps of the chitosan-supported chiral ionic liquid titanium catalyst include: a) reacting 1-vinylimidazole with bromopropionic acid to generate a double-bonded ionic liquid compound containing a carboxylic acid group: 1-vinyl-3-propionic acid imidazole bromide; b) The double-bonded ionic liquid compound containing a carboxylic acid group reacts with chitosan dissolved in a dilute acid solution to obtain a chitosan-functionalized vinyl ionic liquid II, the general formula of which is: c) reacting the obtained chitosan functionalized vinyl ionic liquid II with a chiral amino acid to obtain a chitosan functionalized chiral amino acid vinyl ionic liquid, wherein the chiral amino acid is L-proline, L-phenylalanine, L-leucine, L-histidine, or L-isoleucine, and the reaction formula is: d) Based on the controlled scission-chain transfer free radical polymerization method, azobisisobutyronitrile is used as a chain initiator and carbon thioester is used as a molecular weight regulator to controllably polymerize the chiral amino acid vinyl ionic liquid functionalized with chitosan obtained in step c) to generate a polymer, wherein the carbon thioester is: The reaction formula is e) finally complexing the polymer obtained in step d) with a metal titanium salt to obtain the chitosan-supported chiral ionic liquid titanium catalyst, wherein the metal titanium salt used is tetraisopropoxytitanium; The general formula of the chitosan-supported chiral ionic liquid titanium catalyst is: In formula (1), both * are of S configuration; R1 is selected from the corresponding group in the chiral amino acid in step c) above; R2 is benzyl; R3 is ethyl.

2. The method for efficiently producing esomeprazole sodium based on mobile phase according to claim 1, characterized in that, In step S2, the raw material omeprazole sulfide and a hydrogen peroxide solution with a mass fraction of 25-35 wt% are continuously injected into the microchannel reactor in a ratio of 1:1.2 to carry out an oxidation reaction.

3. The method for efficiently producing esomeprazole sodium based on mobile phase according to claim 1, characterized in that, In step S2, the solvent used in the reaction is water, and the flow rate of the solution is 1-3 mL / min.

4. The method for efficiently producing esomeprazole sodium based on mobile phase according to claim 1, characterized in that, In step S2, the temperature in the reactor is maintained at room temperature.

5. The method for efficiently producing esomeprazole sodium based on mobile phase according to claim 1, characterized in that, In step S4, the organic solvent is selected from dichloromethane, anhydrous ethanol, tetrahydrofuran or toluene.

Citation Information

Patent Citations

  • Method for synthesizing esomeprazole sodium

    CN103044402B

  • Method for high enantiomer selection preparation of (S)-Omeprazole

    CN1810803B

  • Process for synthesis of substituted sulphoxides

    WO1996002535A1

  • Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts

    WO2003089408A2

  • Load-type vanadium chiral catalyst for asymmetric synthesis of esomeprazole and preparation method thereof

    CN106345526A